Protagonist Therapeutics, Inc.
PTGXNASDAQHealthcare● Active
$98.03
+$0.65(+0.67%)
Market Cap$6.3B
P/E Ratio—
52W High$107.84
52W Low$49.38
Protagonist Therapeutics, Inc.（PTGX）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · PTGX · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M |
| Cost of Revenue | $1.23M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $44.79M | $434.43M | $60.00M | $26.58M | $27.36M |
| Gross Margin %(computed) | 97.34% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $159.29M | $138.13M | $120.16M | $126.22M | $126.01M |
| G&A Expenses | $44.85M | $43.46M | $33.49M | $31.74M | $27.20M |
| Total Operating Expenses | $202.92M | $181.59M | $153.65M | $157.95M | $153.20M |
| Operating Income | ($158.13M) | $252.84M | ($93.65M) | ($131.37M) | ($125.84M) |
| Operating Margin %(computed) | -343.63% | 58.20% | -156.09% | -494.24% | -460.01% |
| Interest Income | $28.79M | $26.32M | $14.90M | $4.06M | $0.44M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($129.31M) | $279.41M | ($78.95M) | ($127.39M) | ($125.55M) |
| Income Tax Expense | $0.84M | $4.22M | $0.00M | $0.00M | $0.00M |
| Net Income | ($130.15M) | $275.19M | ($78.95M) | ($127.39M) | ($125.55M) |
| Net Margin %(computed) | -282.83% | 63.34% | -131.59% | -479.26% | -458.94% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.05 | $4.47 | $-1.39 | $-2.52 | $-2.65 |
| Wtd Avg Shares | 63.57M | 61.57M | 56.76M | 49.04M | 46.32M |
| EBITDA | ($128.09M) | $253.67M | ($90.34M) | ($128.00M) | ($123.07M) |
| EBITDA Margin %(computed) | -278.35% | 58.39% | -150.57% | -481.56% | -449.87% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · M
深入了解Protagonist Therapeutics, Inc.
关于Protagonist Therapeutics, Inc.（PTGX）损益表
Protagonist Therapeutics, Inc.（PTGX）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，PTGX实现营收$0.05B，毛利润$0.04B（毛利率97.34%），净利润($0.13B)（净利率-282.83%）。
常见问题
PTGX · 4 问Protagonist Therapeutics, Inc.（PTGX）2025财年营收为$0.05B，同比down89.4%。
PTGX revenuePTGX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08